Jorge Canto

New paper out! 📊 Live birth rates are lower after IPAA vs UC patients without IPAA & the general population—and lap IPAA doesn’t close the gap. C-section rates are also significantly higher. Important data for counseling patients. onlinelibrary.wiley.com/doi/epdf/10.11…

@AnthonydeBuck @mantaj_brar Congratulations great work

🎓 Inside ESCP Education The European Society of Coloproctology Education Committee, chaired by Michel Adamina, drives key programmes: 🔹 ESCP School 🔹 Webinar Programme 🔹 Fellowships (robotic, pelvic floor, exchanges) 🔹 Masterclasses & regional courses 🔹 Scientific programme development 📅 More every Mon & Fri during April #ESCP #ColorectalSurgery #MedEd #GlobalSurgery

JSES IllustCon 123 📌Landmark-guided TaTME-assisted Laparoscopic Low Anterior Resection 📝TaTME enables excellent visualization and precise dissection in the deep pelvis through simultaneous approaches from the abdominal and perineal sides. Anatomic landmarks can be identified to perform a safe and highly curative surgery. 🖊SHIGAKI TAKAHIRO #JSESイラストコンテスト　#JSES_illustration_contest

@caycedomarula @orlandohealth Congrats, awesome

Wednesday @OrlandoHealth cases 1, 2 & 3 of the first FDA-approved magnetic colorectal anastomosis trial in the world All three successful. Immediate patency confirmed This tech is everything I believed it would be. The trial continues. #ColorectalSurgery #MagneticAnastomosis

@ameerfarooq Same !

As a nap enthusiast I approve of this message.

In adults with uncomplicated #appendicitis, 44% treated with antibiotics required appendectomy within 10 years, but complication rates were lower and quality of life similar to surgery. ja.ma/3NU446Z

March = Colorectal Cancer Awareness Month 3 things to know 👇 ✔️ Early detection = 90% survival ✔️ Not just “older people” (rising in 30s & 40s) ✔️ Fiber + movement can cut risk by 50%+ Simple home FIT tests = easy, private & lifesaving If you’re 40+, check in this month. #ECCAM2026 #EarlyDetection #HealthTips digestivecancers.eu @dice.europe

@VictorPerimMD @UABSurgery @JBartRose @DrReddy_HPB @andreagillis Congratulations, my friend—I never doubted you for a second.

I am going to be a surgeon…🥹🔪 🤩 … and AT THE BEST PLACE OF ALL @UABSurgery 💚 Thank you ONE BILLION TIMES to my mentors @JBartRose @DrReddy_HPB @andreagillis CANT WAIT to scrub in with my heroes 🥺

New study! Phase 3 ORCHESTRA trial tested whether adding aggressive tumor debulking to systemic therapy improves outcomes in patients with advanced CRC: 👉No survival benefit.😳@ASCRS_1 @escp_tweets @AmCollegeGastro @FightCRC

@drkeithsiau @ameerfarooq Scary 😱

Chaotic scenes on colonoscopy. What is the likely cause of bleeding here?

Nuestro nuevo metaanálisis sobre HI tras laparotomía media. ¿Qué tan frecuente es y qué factores realmente aumentan el riesgo de desarrollarla? Analizamos datos de casi 800,000 pacientes. La prevalencia global de HI es del 10.1%. Los mayores FR (¡Superan a las comorbilidades!).

Master the surgical anatomy of laproscopic inguinal hernia. Key concepts: Direct vs Indirect hernia, Femoral hernia, Triangle of Doom, Triangle of Pain, Iliopubic tract, Inferior epigastric vessels, and ASIS landmarks. A quick visual guide on this high-yield topic.

@ameerfarooq @CAGS_ACCG @CanGastroAssn @RobertBechara @Hookeyl @ASCRS_1 @SAGES_Updates @rbarbosa91 @BoutrosMarylise @caycedomarula Great topic! I’d be very interested to hear what’s happening on the surgical side.

Are there unintended consequences of #AI in surgery and endoscopy? 🤔 Would love to see folks there and get a good discussion going! @CAGS_ACCG @CanGastroAssn @RobertBechara @Hookeyl @ASCRS_1 @SAGES_Updates @rbarbosa91 @BoutrosMarylise @caycedomarula

Or maybe not 🫣

Last year of surgical training .. 🔪

New tool alert 🚨 The Atlantic Pouchitis Index (API) brings objective, validated assessment to pouchitis 📊🔬 Better measurement = better care ✨ @AGA_CGH #CGH4ALL

Colorectal Cancer: ITE/Boards Review pearls (See ASCO/NCCN for latest updates) 1. 🌎 Epidemiology 150K US cases/yr; ↓incidence (screening); ↑early-onset (<50, #1 cancer death men <50). Young CRC → hereditary until proven otherwise. 🧬 Hereditary 1. FAP (carpet of polyps)-mandatory prophylactic colectomy- Gene-APC (AD)- No of polyps 100s-1000s, other key features includes Desmoids, duodenal CA, 100% CRC risk → colectomy 2. Lynch syndrome: MMR (MLH1/MSH2/MSH6/PMS2; AD)- No of polyps- Dozens- Key features includes Endometrial #1, extracolonic; MSI-H/dMMR ***MMR/MSI Testing: Universal in ALL CRC. IHC dimers: MLH1+PMS2; MSH2+MSH6. MLH1 loss → BRAF-/methyl neg → germline*** 🔎 Screening Start age 45 (avg risk); colonoscopy gold std. 2. Early-Stage Management (I–III) ->Stage II MSI-High: DO NOT give 5-FU. Better prognosis; no benefit from adjuvant fluoropyrimidines. ->Stage II MSS: Chemo only for High-Risk (T4, <12 nodes, perforation, obstruction, LVI/PNI). ->Stage III (The IDEA Trial): All get chemo (FOLFOX/CAPOX). -Low Risk (T1–3 N1): 3 months CAPOX is non-inferior and preferred (reduces neuropathy). -High Risk (T4 or N2): 6 months (FOLFOX/CAPOX). ->T4 Staging: T4a = Visceral peritoneum; T4b = Adjacent organs 3. Rectal ->Staging: Pelvic MRI is mandatory. ->Principles: Neoadjuvant CRT (long-course) preferred over adjuvant. ->TNT (Total Neoadjuvant Therapy): Induction/Consolidation chemo + CRT before surgery is the modern standard to improve DFS and organ preservation. ->PROSPECT Trial: Select low-risk T3 can receive FOLFOX alone (avoiding radiation). ->Wait-and-Watch: For clinical complete responders (cCR); strictly monitored. ->Adjuvant Rule: Post-op chemo is based on pre-treatment clinical stage, not the path report. ***Colon vs Rectal: Colon no neoadjuvant/RT; rectal yes*** 🧬 mCRC 1L (MSS) -->Left RAS WT(Wild Type) → EGFR Curability: Resectable liver-only disease can be cured. Evaluation by a liver surgeon is mandatory. The "Sidedness" Rule (RAS Wild-Type): ->Left-Sided: Chemo + EGFR mAb (Cetuximab/Panitumumab) is first-line. ->Right-Sided: Chemo + Bevacizumab (EGFR mAbs don't work as well here). Maintainance: Drop ox → Cap/BEV. Continue BEV beyond progress. RAS Mutant: NEVER use EGFR antibodies. Use Bevacizumab/VEGF inhibitors. BiomarkerTherapy (2L+) ->BRAF V600E-->Encorafenib + cetux-->No EGFR+chemo alone ->HER2 amp-->Trastuzumab+tucatinib or T-DXd (ILD risk)-->RAS WT -->KRAS G12C-->G12Ci + cetux-->Despite RAS mut -->MSI-HPD-1 1L- 3L+: TAS-102+BEV (pref), regorafenib (low-escalate), fruquintinib 🔥 Liver Mets (Curable!) -->Limited liver-only → resect (peri-op FOLFOX ↑DFS). -->NO cetuximab (EPOC harm). Stop BEV 6 wks pre-op. Conversion OK. -->Traps: MSI-low=MSS; Stage II MSI-H no chemo; screen at 45Yr; left RAS WT=EGFR; universal testing 1L= First line, 2L= Second line, 3L= Third line #CRC #ColorectalCancer #OncTwitter #MedEd #OncologyBoards #ABIM #PrecisionMed @ASCO @NCCNorg @OncLive @IMG_Oncologists #CRC #OncTwitter #ABIM Follow: X@MamthaB/ Insta-@ Hemonc_dr

#Marchblue arriving! #SCREESCO trial results showing importance of #screeningcoloncancer @sbcp @ASCRS_1 @escp_tweets @ColonCancerCoal @CCAlliance @AmCollegeGastro